Docosahexaenoic acid

Drug Profile

Docosahexaenoic acid

Alternative Names: Altemia; Doconexent; SC-411

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sancilio & Company
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Sickle cell anaemia

Most Recent Events

  • 01 Nov 2017 Efficacy and adverse events data from a phase II trial in Sickle cell anaemia released by Sancillo Pharmaceuticals
  • 01 Nov 2017 Sancillo Pharmaceuticals plans a phase II extension trial for Sickle cell anaemia in USA
  • 09 Oct 2017 CTP push NCT02973360 - trial completion info is already covered from MR
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top